reni-cel RUBY Long-term Follow-up — ASGCT 2026

EDIT·reni-cel·Sickle Cell Disease·

Phase 3

·NCT05444894

current best date

MAY–MAY

2026

WINDOW12 days

Takeaway

Long-term reni-cel follow-up at ASGCT 2026 — preview ahead of the year-end ASH update. Watch: durability of HbF elevation and VOC freedom; comparison to CASGEVY benchmarks.

What’s at stake

market · comparables · base rate · prior moves

Market opportunity

—

company filings

Peer comparables

1 readout

ClinicalTrials.gov

Stage base rate

~58%

BIO Industry Analysis 2023 (2011–2020)

Avg prior-readout move

—

historical price reactions

MoACRISPR/Cas12a HBG1/2 promoter edit

Reni-cel is Editas Medicine's ex vivo gene-editing therapy for sickle cell disease and beta thalassemia that uses CRISPR/Cas12a — rather than the more common Cas9 — to edit patient-derived blood stem cells and reactivate fetal hemoglobin production. After the edited cells are reinfused following conditioning chemotherapy, elevated fetal hemoglobin compensates for defective adult globin, preventing red blood cell sickling and reducing transfusion dependence. Editas positions reni-cel as a next-generation alternative to CASGEVY, with the hypothesis that Cas12a provides a distinct precision profile at the BCL11A enhancer locus.

Indication

Oncology - Heme

Sickle Cell Disease

MeSH · D000755

No primer in glossary yet.

Trial

active

NCT05444894 ↗

RUBY Phase 1/2 Reni-cel in SCD

Glossary · what this readout is measuring

1 term detected in the takeaway

ASHconference
American Society of Hematology Annual Meeting
The major heme/onc meeting (~30,000 attendees). Early-December; key venue for blood cancer and rare hematology readouts.

Competitive landscape

4 peers in Oncology - Heme · ranked by indication + modality match

Drug	Company	Modality	Mechanism	Next catalyst
BEAM-101	BEAM	cell therapy	base editing of HBG1/2 to reactivate fetal hemoglobin	READOUT · Dec 26
CASGEVYexagamglogene autotemcel	CRSP	cell therapy	CRISPR/Cas9 BCL11A enhancer edit	CONFERENCE · Dec 26
CB-010	CRBU	cell therapy	allogeneic CRISPR-edited anti-CD19 CAR-T	CONFERENCE · May 26
JAKAFIruxolitinib	INCY	small molecule	JAK1/JAK2 inhibitor	READOUT · Sep 26

Disclosure trail

1 observation · sorted by confidence

Apr 12, 2026·18d agopinned · highest confidence
HIGH confPR
top claim
MAY–MAY2026
WINDOW
“Editas will present long-term follow-up data from the RUBY Phase 1/2 study of reni-cel at the ASGCT 28th Annual Meeting (May 12–15, 2026, San Diego).”
conf 93%via llm

MethodologyEvery catalyst date is anchored to a primary source. Disclosures with confidence ≥ 0.85 auto-publish; the rest are reviewed by a human within 24 hours. We never interpret data — we organize public information.